These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34857694)

  • 21. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.
    Hayashi Y; Lipman J; Udy AA; Ng M; McWhinney B; Ungerer J; Lust K; Roberts JA
    Int J Antimicrob Agents; 2013 Feb; 41(2):162-6. PubMed ID: 23153962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review.
    Alshaer M; Mazirka P; Burch G; Peloquin C; Drabick Z; Carson J
    J Burn Care Res; 2023 Jan; 44(1):121-128. PubMed ID: 35896122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
    Gonçalves-Pereira J; Póvoa P
    Crit Care; 2011; 15(5):R206. PubMed ID: 21914174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
    Tängdén T; Ramos Martín V; Felton TW; Nielsen EI; Marchand S; Brüggemann RJ; Bulitta JB; Bassetti M; Theuretzbacher U; Tsuji BT; Wareham DW; Friberg LE; De Waele JJ; Tam VH; Roberts JA;
    Intensive Care Med; 2017 Jul; 43(7):1021-1032. PubMed ID: 28409203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review.
    Boidin C; Moshiri P; Dahyot-Fizelier C; Goutelle S; Lefeuvre S
    Anaesth Crit Care Pain Med; 2020 Feb; 39(1):87-109. PubMed ID: 31513935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome.
    Koch BCP; Muller AE; Hunfeld NGM; de Winter BCM; Ewoldt TMJ; Abdulla A; Endeman H
    Ther Drug Monit; 2022 Feb; 44(1):11-18. PubMed ID: 34772892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens.
    Fuchs A; Li G; van den Anker JN; Bielicki J
    Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment.
    Chiriac U; Frey OR; Roehr AC; Koeberer A; Gronau P; Fuchs T; Roberts JA; Brinkmann A
    Medicine (Baltimore); 2021 Jun; 100(22):e26253. PubMed ID: 34087915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
    Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
    Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
    Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
    Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France.
    Charmillon A; Novy E; Agrinier N; Leone M; Kimmoun A; Levy B; Demoré B; Dellamonica J; Pulcini C
    Clin Microbiol Infect; 2016 Jul; 22(7):625-31. PubMed ID: 27145210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
    Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
    Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE
    Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Antibiotics in Sub-Saharan African Patient Populations: A Systematic Review.
    Bos JC; van Hest RM; Prins JM
    Ther Drug Monit; 2017 Aug; 39(4):387-398. PubMed ID: 28703719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
    Smekal AK; Furebring M; Eliasson E; Lipcsey M
    Sci Rep; 2022 Dec; 12(1):21891. PubMed ID: 36535989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A guide to therapeutic drug monitoring of β-lactam antibiotics.
    Fratoni AJ; Nicolau DP; Kuti JL
    Pharmacotherapy; 2021 Feb; 41(2):220-233. PubMed ID: 33480024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper
    Abdul-Aziz MH; Alffenaar JC; Bassetti M; Bracht H; Dimopoulos G; Marriott D; Neely MN; Paiva JA; Pea F; Sjovall F; Timsit JF; Udy AA; Wicha SG; Zeitlinger M; De Waele JJ; Roberts JA; ; ; ;
    Intensive Care Med; 2020 Jun; 46(6):1127-1153. PubMed ID: 32383061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
    Roberts JA; Paul SK; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Clin Infect Dis; 2014 Apr; 58(8):1072-83. PubMed ID: 24429437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic drug monitoring of β-lactam antibiotics].
    Tanha N; Bathum L; Munk JK; Frimodt-Møller N; Andersen CØ; Benfield T
    Ugeskr Laeger; 2020 Sep; 182(39):. PubMed ID: 33000734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.